Loading clinical trials...
Loading clinical trials...
A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options
Conditions
Interventions
Abatacept
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
+1 more
Locations
148
United States
Local Institution
Birmingham, Alabama, United States
Local Institution
Huntsville, Alabama, United States
Local Institution
Paradise Valley, Arizona, United States
Local Institution
Peoria, Arizona, United States
Local Institution
Tucson, Arizona, United States
Local Institution
Long Beach, California, United States
Start Date
April 1, 2005
Primary Completion Date
August 1, 2009
Completion Date
August 1, 2009
Last Updated
February 27, 2012
NCT06647069
NCT07484243
NCT06841562
NCT07268326
NCT07233655
NCT07029555
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions